NOVOB/N Stock Price and Chart — BIVA:NOVOB/N — TradingView

Overview

Financials News Ideas Discussions Forecast Seasonals Bonds

NOVOB/N chart

Key facts today

Berenberg has reduced its target price for Novo Nordisk to DKK 725 from DKK 975, while Jefferies has lowered its target price to DKK 515 from DKK 575.

Analyze the impact Analyze the impact

NOVOB/N upcoming earnings

Key stats

Employees

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Financials

Performance

Revenue to profit conversion

Debt level and coverage

Earnings

Next:—

Ideas

See all ideas

Technicals

Summarizing what the indicators are suggesting.

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

An aggregate view of professional's ratings.

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Neutral

SellBuy

Strong sellStrong buy

Strong sellSellNeutralBuyStrong buy

Seasonals

Displays a symbol's price movements over previous years to identify recurring trends.

NOVOB/N highest yielding bonds

N

3.29%

May 21, 2034

N

3.02%

Jan 21, 2031

2.99%

Mar 31, 2030

N

2.88%

Jan 21, 2029

2.85%

Jun 4, 2028

2.81%

Mar 31, 2025

N

2.78%

May 21, 2026

2.64%

Sep 30, 2027

Explore more bonds

Curated watchlists where NOVOB/N is featured.

Big pharma stocks: Top pharmaceutical firms

Biotech stocks: A shot in the arm

See all sparks

The current price of NOVOB/N is 1,670.00 MXN — it has decreased by −25.93% in the past 24 hours. Watch NOVO NORDISK A/S stock price performance more closely on the chart.

Depending on the exchange, the stock ticker may vary. For instance, on BIVA exchange NOVO NORDISK A/S stocks are traded under the ticker NOVOB/N.

NOVOB/N stock has fallen by −25.09% compared to the previous week, the month change is a −25.09% fall, over the last year NOVO NORDISK A/S has showed a −16.98% decrease.

We've gathered analysts' opinions on NOVO NORDISK A/S future price: according to them, NOVOB/N price has a max estimate of 3,276.27 MXN and a min estimate of 1,467.20 MXN. Watch NOVOB/N chart and read a more detailed NOVO NORDISK A/S stock forecast: see what analysts think of NOVO NORDISK A/S and suggest that you do with its stocks.

NOVOB/N stock is 35.01% volatile and has beta coefficient of 1.41. Track NOVO NORDISK A/S stock price on the chart and check out the list of the most volatile stocks — is NOVO NORDISK A/S there?

Today NOVO NORDISK A/S has the market capitalization of ‪8.02 T‬, it has decreased by −19.74% over the last week.

Yes, you can track NOVO NORDISK A/S financials in yearly and quarterly reports right on TradingView.

NOVO NORDISK A/S is going to release the next earnings report on Feb 5, 2025. Keep track of upcoming events with our Earnings Calendar.

NOVOB/N earnings for the last quarter are 18.00 MXN per share, whereas the estimation was 17.64 MXN resulting in a 2.03% surprise. The estimated earnings for the next quarter are 17.84 MXN per share. See more details about NOVO NORDISK A/S earnings.

NOVO NORDISK A/S revenue for the last quarter amounts to ‪209.69 B‬ MXN, despite the estimated figure of ‪212.08 B‬ MXN. In the next quarter, revenue is expected to reach ‪232.25 B‬ MXN.

NOVOB/N net income for the last quarter is ‪80.28 B‬ MXN, while the quarter before that showed ‪52.70 B‬ MXN of net income which accounts for 52.33% change. Track more NOVO NORDISK A/S financial stats to get the full picture.

NOVO NORDISK A/S dividend yield was 1.35% in 2023, and payout ratio reached 50.35%. The year before the numbers were 1.32% and 50.59% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.

As of Jan 7, 2025, the company has ‪63.37 K‬ employees. See our rating of the largest employees — is NOVO NORDISK A/S on this list?

EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVO NORDISK A/S EBITDA is ‪398.52 B‬ MXN, and current EBITDA margin is 47.96%. See more stats in NOVO NORDISK A/S financial statements.

Like other stocks, NOVOB/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVO NORDISK A/S stock right from TradingView charts — choose your broker and connect to your account.